Showing 1 - 12 results of 12 for search 'Bjorn Dahlof', query time: 0.03s Refine Results
  1. 1
    Valsartan and the renin-angiotensin-aldosterone system: Blood pressure control and beyond

    Valsartan and the renin-angiotensin-aldosterone system: Blood pressure control and beyond by Björn Dahlöf

    Published 2000-06-01
    Get full text
    Article
  2. 2
    Valsartan and the renin-angiotensin-aldosterone system: blood pressure control and beyond

    Valsartan and the renin-angiotensin-aldosterone system: blood pressure control and beyond by Björn Dahlöf

    Published 2000-06-01
    Get full text
    Article
  3. 3
    Compound 21, the first orally active, selective agonist of the angiotensin type 2 receptor (AT2): implications for AT2 receptor research and therapeutic potential

    Compound 21, the first orally active, selective agonist of the angiotensin type 2 receptor (AT2): implications for AT2 receptor research and therapeutic potential by Thomas Unger, Björn Dahlöf

    Published 2010-03-01
    Get full text
    Article
  4. 4
    S309: SUSTAINED INHIBITION OF PLATELET ACTIVITY AND THROMBOSIS VIA IV AND ORAL ADMINISTRATION OF CS585

    S309: SUSTAINED INHIBITION OF PLATELET ACTIVITY AND THROMBOSIS VIA IV AND ORAL ADMINISTRATION OF CS585 by Sylviane Lambert, Andrew Rickenberg, Bjorn Dahlof, Niklas Bergh, Michael Holinstat

    Published 2023-08-01
    Get full text
    Article
  5. 5
    Telmisartan Effectiveness on Left ventricular MAss Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension — a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months — rationale and study design

    Telmisartan Effectiveness on Left ventricular MAss Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension — a prospective, rand... by Matthias G Friedrich, Björn Dahlöf, Udo Sechtem, Thomas Unger, Mathias Knecht, Rainer Dietz, TELMAR Investigators

    Published 2003-12-01
    Get full text
    Article
  6. 6
    CS1, a controlled‐release formulation of valproic acid, for the treatment of patients with pulmonary arterial hypertension: Rationale and design of a Phase 2 clinical trial

    CS1, a controlled‐release formulation of valproic acid, for the treatment of patients with pulmonary arterial hypertension: Rationale and design of a Phase 2 clinical trial by Raymond L. Benza, Philip B. Adamson, Deepak L. Bhatt, Fredrik Frick, Gunnar Olsson, Niklas Bergh, Björn Dahlöf

    Published 2024-01-01
    Get full text
    Article
  7. 7
    Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression

    Influence of diabetes on efficacy of aliskiren, losartan or both on left ventricular mass regression by Orly Vardeny, Anne-Catherine Pouleur, Madoka Takeuchi, Evan Appelbaum, Anil Verma, Margaret Prescott, Beverly Smith, Bjorn Dahlof, Scott D Solomon

    Published 2012-06-01
    Get full text
    Article
  8. 8
    Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study

    Higher pulse pressure/stroke volume index is associated with impaired outcome in hypertensive patients with left ventricular hypertrophy the LIFE study by Costantino Mancusi, Eva Gerdts, Giovanni de Simone, Helga Midtbø, Mai Tone Lønnebakken, Kurt Boman, Kristian Wachtell, Björn Dahlöf, Richard B. Devereux

    Published 2017-05-01
    Get full text
    Article
  9. 9
    Telomere length is associated with ACE I/D polymorphism in hypertensive patients with left ventricular hypertrophy

    Telomere length is associated with ACE I/D polymorphism in hypertensive patients with left ventricular hypertrophy by Frej Fyhrquist, Anders Eriksson, Outi Saijonmaa, Børge G Nordestgaard, Kimmo Kontula, Ulf de Faire, Hans Ibsen, Sverre Kjeldsen, Ingrid Os, Björn Dahlöf

    Published 2013-09-01
    Get full text
    Article
  10. 10
    Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension

    Suppression of aldosterone mediates regression of left ventricular hypertrophy in patients with hypertension by Anne-Catherine Pouleur, Hajime Uno, Margaret F Prescott, Akshay Desai, Evan Appelbaum, Valentina Lukashevich, Beverly A Smith, Björn Dahlöf, Scott D Solomon

    Published 2011-12-01
    Get full text
    Article
  11. 11
    Prior Medications and the Cardiovascular Benefits From Combination Angiotensin‐Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High‐Risk Hypertensive Patients

    Prior Medications and the Cardiovascular Benefits From Combination Angiotensin‐Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High‐Risk Hypertensive Patients by Robert D. Brook, Niko Kaciroti, George Bakris, Björn Dahlöf, Bertram Pitt, Eric Velazquez, Michael Weber, Dion H. Zappe, Tsushung Hau, Kenneth A. Jamerson

    Published 2018-01-01
    Get full text
    Article
  12. 12
    Direct angiotensin II type 2 receptor stimulation ameliorates insulin resistance in type 2 diabetes mice with PPARγ activation.

    Direct angiotensin II type 2 receptor stimulation ameliorates insulin resistance in type 2 diabetes mice with PPARγ activation. by Kousei Ohshima, Masaki Mogi, Fei Jing, Jun Iwanami, Kana Tsukuda, Li-Juan Min, Akiyoshi Ogimoto, Björn Dahlöf, Ulrike M Steckelings, Tomas Unger, Jitsuo Higaki, Masatsugu Horiuchi

    Published 2012-01-01
    Get full text
    Article

Search Tools: